- Home
- PASG vs IGC Comparison
PASG vs IGC Comparison
Compare PASG & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | IGC |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 28.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PASG | IGC |
|---|---|---|
| Price | $8.90 | $0.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $34.50 | $4.13 |
| AVG Volume (30 Days) | 57.7K | ★ 421.1K |
| Earning Date | 03-03-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.12 | $0.24 |
| 52 Week High | $20.00 | $0.50 |
Technical Indicators
Market Signals| Indicator | PASG | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 35.75 |
| Support Level | $8.86 | $0.27 |
| Resistance Level | $10.63 | $0.30 |
| Average True Range (ATR) | 1.38 | 0.01 |
| MACD | -0.45 | -0.00 |
| Stochastic Oscillator | 1.46 | 17.65 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.